Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IX-01 · 1 trial · 1 indication
IX-01 versus placebo. Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred
| Arm | Type | Description |
|---|---|---|
| Drug: IX-01 | EXPERIMENTAL | Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity |
| Placebo | PLACEBO_COMPARATOR | Two to four capsules administered orally, 1-6 hours prior to sexual activity |
| Name | Type | Description |
|---|---|---|
| IX-01 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * In stable (≥ 6 months) heterosexual relationship * Have life-long (primary) premature ejaculation * Have premature ejaculation confirmed by Intravaginal Ejaculatory Latency Time (IELT) less than or equal to (≤) 1 minute on ≥ 75% attempts at sexual intercourse * Meet other aspe...
IX-01 is an investigational small molecule being developed for the treatment of premature ejaculation. It is currently in Phase 2 clinical development and has been studied in a completed clinical trial to evaluate its effect on intravaginal ejaculatory latency time and patient-reported outcomes in men with this condition.
IX-01 is being developed by Icon Plc, a company listed on the stock exchange under the ticker ICLR. The drug is currently in Phase 2 clinical development for the treatment of premature ejaculation.
IX-01 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy for the treatment of premature ejaculation.
IX-01 has been studied in one completed clinical trial with the identifier NCT02232425. This Phase 2 trial evaluated the effect of IX-01 on intravaginal ejaculatory latency time and patient-reported outcomes in men with premature ejaculation. The trial enrolled 88 participants and was conducted in the United States and Australia.
No alternative names for IX-01 have been reported. The drug is known only by its development code IX-01 and is being studied for the treatment of premature ejaculation.